Newcells Biotech’s New Lung Assay Could Transform Respiratory Diagnostics

Newcells Biotech, a leader in drug discovery and custom assay development, has introduced its innovative CiliaBeat software alongside a new Lung Ciliary Beat Frequency Analysis assay. This advanced software helps researchers evaluate how drugs and chemicals impact the tiny, ciliated cells in the lung's small airways.

The CiliaBeat software has been rigorously tested with Newcells’ specialized small airway epithelial cell model, proving its accuracy and reliability for assessing drug safety and effectiveness in early-stage development. The new Lung Ciliary Beat Frequency Analysis assay, designed to maximize the potential of CiliaBeat, adds to Newcells’ suite of services. It provides dependable and predictive data on the function of cilia in the airways, enhancing the research capabilities in pre-clinical drug testing.

The technology enables the evaluation of dosing effects on mucus clearance, cilia function, and the effectiveness of drugs in reversing disease-related conditions. These factors are crucial for advancing drug discovery and development, particularly for treating lung diseases like Chronic Obstructive Pulmonary Disorder (COPD) and bronchiectasis, as well as assessing the effects of airborne pollutants.

CiliaBeat was created to fill a gap in the market for a software that combines high sensitivity, stability, and speed. This innovative tool enhances the Company’s recently introduced high-content and high-throughput imaging suite, solidifying Newcells' position as a leader in providing advanced imaging solutions. It meets the increasing demand for comprehensive and predictive preclinical studies.

The advanced software offers swift, unbiased analysis by optimizing video inputs of ciliated cell movements while reducing background noise. High-definition videos are captured through a specially designed setup that boosts sensitivity, producing precise and detailed datasets. This facilitates quicker program progression and informed selection of lead compounds, including those for fast-acting medications.

Dr Mike Nicholds, CEO and Co-Founder, Newcells Biotech, commented, “Our team is highly experienced in development of robust and predictive assays for drugs targeting the lung. CiliaBeat complements our existing capabilities, giving customers more options to gain physiologically-relevant insights into this crucial organ type.

He further added, "We prioritise innovation, driving forward the scale and depth of offerings to customers, to support faster, more informed decision-making and accelerate their drug development processes. Building on our cutting-edge imaging suite, the new ciliary beat frequency assay does just that, enabling us to provide predictive data that optimises our customers' development pathway.”